NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
7 September 2023
ImmuPharma Plc
("ImmuPharma" or the "Company")
Result of Retail Offer and Director Shareholding
ImmuPharma Plc is pleased to announce that further to the Company's announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of £130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform ("WRAP"), in addition to the £1.35 million raised in the Subscription and Direct Subscription.
An application has been made to the London Stock Exchange for the 6,534,150 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place, and dealings on AIM in the Retail Offer Shares are expected to commence, at 8.00 a.m. on or around 12 September 2023.
Director Dealing
Lisa Baderoon, Director, subscribed for 1,000,000 Retail Offer Shares in the Retail Offer. Following Admission, Lisa Baderoon's shareholding will be 1,583,963 Ordinary Shares comprising 0.38% of the issued share capital.]
Total Voting Rights
Following Admission, the Company will have 416,437,265 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 416,437,265. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company at 7:02 a.m. on 31 August 2023.
For Further Information
| ImmuPharma plc | |
| Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations | +44 (0) 207 206 2650 + 44 (0) 7721 413496 |
|
Stanford Capital Partners | |
| Patrick Claridge Bob Pountney | +44 (0) 203 650 3650 |
| | |
| SPARK Advisory Partners Limited | +44 (0) 203 368 3554 |
| Neil Baldwin | +44 (0) 113 370 8974 |
|
| |
| Winterflood Retail Access Platform | WRAP@winterflood.com |
| Alex Skrine, Head of Electronic Trading | +44 (0) 20 3100 0000 |
| Phoebe Pankhurst, Corporate Finance Haris Khawaja, Corporate Finance | |
Further information on the Company can be found on its website at https://www.immupharma.co.uk/
The Company's LEI is 213800VZKGHXC7VUS895
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Lisa Baderoon | ||||
| 2 | Reason for notification | |||||
| a) | Position / status | Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | ImmuPharma Plc | ||||
| b) | LEI | 213800VZKGHXC7VUS895 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1p (£0.01) each in the capital of ImmuPharma plc ISIN GB0033711010
| ||||
| | Nature of the transaction | Subscription in retail offer | ||||
| | Price(s) and volumes(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Aggregated price |
1,000,000 £0.02 | ||||
| e) | Date of the transaction | 7 September 2023 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
